Systematic review: antibodies and anti-TNF- levels in inflammatory bowel disease
Alimentary Pharmacology and Therapeutics, 04/12/2012Chaparro M et al.
Measurement of serum anti–TNF– α trough levels and antibody titres could prove useful in therapeutic drug monitoring in inflammatory bowel disease (IBD) patients treated with anti–TNF– α agents.
A systematic review was undertaken based on electronic searches of the PubMed database from the earliest record to February 2012.
The reference lists of all relevant articles and abstracts from meetings were also consulted.
The authors observed a close relationship between trough levels of anti-TNF- α drug and maintenance of response to these drugs.
The role of antibodies in loss of response seems to be limited to their effect favouring the clearance of the drug.
The risk of infusion reactions, but not of delayed hypersensitivity reactions, is higher in patients with antibodies against the anti-TNF-α drug.
Testing anti-TNF-α drug and antibody levels, together with clinical and endoscopic or radiological assessment, seems useful when attempting to optimise therapy and prevent inappropriate management of IBD patients.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.